发泡剂天然载体 TrichoFoam™ 中咖啡因氯倍他索丙酸盐度他雄胺烟酰胺和黄体酮的兼容性。

Q4 Medicine International journal of pharmaceutical compounding Pub Date : 2024-03-01
Hudson C Polonini, Pamela Lopes de Sousa, Carolina Cv Silva, Bruna Marianni
{"title":"发泡剂天然载体 TrichoFoam™ 中咖啡因氯倍他索丙酸盐度他雄胺烟酰胺和黄体酮的兼容性。","authors":"Hudson C Polonini, Pamela Lopes de Sousa, Carolina Cv Silva, Bruna Marianni","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Alopecia is a chronic dermatological disorder affecting men and women worldwide. Given the high incidence and significant impact on patients' well-being, options for managing and treating alopecia are essential. Topical available options remain limited and oral products may result in adverse effects. TrichoFoam™ is a ready-to-use foaming vehicle developed for compounding pharmacies and formulated with gentle, non-irritating, and sensory-pleasant ingredients.</p><p><strong>Objective: </strong>The purpose of this study was to assess topical foams' physicochemical and microbiological stabilities of formulations compounded with TrichoFoam™ as the ready-touse vehicle.</p><p><strong>Methods: </strong>HPLC analyses were conducted in a bracketed study covering concentrations of 0.1% to 2.0% of caffeine, 0.01% to 0.1% of clobetasol propionate, 0.1% to 0.25% of dutasteride, 0.25% to 0.50% of nicotinamide, and 0.25% to 2.5% of progesterone compounded with TrichoFoam™. Antimicrobial Effectiveness Testing was conducted at the beginning and end of the studies.</p><p><strong>Results: </strong>Most formulations presented a beyond-use date of at least 90-180 days, except for clobetasol propionate, which showed compatibility for 14 days, and dutasteride 0.25%, which showed a BUD of 30 days.</p><p><strong>Conclusion: </strong>This validates the stability of the active pharmaceutical ingredients from different pharmacological classes with TrichoFoam™, suggesting that this ready-to-use vehicle can be an excellent alternative for personalized alopecia treatment.</p>","PeriodicalId":14381,"journal":{"name":"International journal of pharmaceutical compounding","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Compatibility of Caffeine Clobetasol Propionate Dutasteride Nicotinamide and Progesterone in TrichoFoam™, a Natural Vehicle for Hair Foams.\",\"authors\":\"Hudson C Polonini, Pamela Lopes de Sousa, Carolina Cv Silva, Bruna Marianni\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Alopecia is a chronic dermatological disorder affecting men and women worldwide. Given the high incidence and significant impact on patients' well-being, options for managing and treating alopecia are essential. Topical available options remain limited and oral products may result in adverse effects. TrichoFoam™ is a ready-to-use foaming vehicle developed for compounding pharmacies and formulated with gentle, non-irritating, and sensory-pleasant ingredients.</p><p><strong>Objective: </strong>The purpose of this study was to assess topical foams' physicochemical and microbiological stabilities of formulations compounded with TrichoFoam™ as the ready-touse vehicle.</p><p><strong>Methods: </strong>HPLC analyses were conducted in a bracketed study covering concentrations of 0.1% to 2.0% of caffeine, 0.01% to 0.1% of clobetasol propionate, 0.1% to 0.25% of dutasteride, 0.25% to 0.50% of nicotinamide, and 0.25% to 2.5% of progesterone compounded with TrichoFoam™. Antimicrobial Effectiveness Testing was conducted at the beginning and end of the studies.</p><p><strong>Results: </strong>Most formulations presented a beyond-use date of at least 90-180 days, except for clobetasol propionate, which showed compatibility for 14 days, and dutasteride 0.25%, which showed a BUD of 30 days.</p><p><strong>Conclusion: </strong>This validates the stability of the active pharmaceutical ingredients from different pharmacological classes with TrichoFoam™, suggesting that this ready-to-use vehicle can be an excellent alternative for personalized alopecia treatment.</p>\",\"PeriodicalId\":14381,\"journal\":{\"name\":\"International journal of pharmaceutical compounding\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of pharmaceutical compounding\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of pharmaceutical compounding","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

背景:脱发是一种影响全球男性和女性的慢性皮肤病。鉴于脱发的高发病率和对患者福祉的重大影响,管理和治疗脱发的方案至关重要。局部可用的选择仍然有限,口服产品可能会导致不良反应。TrichoFoam™ 是一种即开即用的发泡载体,专为复方药剂开发,配方中含有温和、无刺激、感官舒适的成分:本研究旨在评估以 TrichoFoam™ 作为即用型载体配制的外用泡沫制剂的理化和微生物稳定性。方法: 在括号内的研究中进行了高效液相色谱分析,涵盖使用 TrichoFoam™ 复配的浓度为 0.1% 至 2.0% 的咖啡因、0.01% 至 0.1% 的氯倍他索丙酸酯、0.1% 至 0.25% 的度他雄胺、0.25% 至 0.50% 的烟酰胺和 0.25% 至 2.5% 的黄体酮。在研究开始和结束时进行了抗菌效果测试:结果:除氯倍他索丙酸酯的相容性为 14 天和 0.25% 度他雄胺的 BUD 为 30 天外,大多数制剂的超期使用时间至少为 90-180 天:结论:这验证了 TrichoFoam™ 对不同药理类别的活性药物成分的稳定性,表明这种即用型载体可以成为个性化脱发治疗的绝佳替代品。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Compatibility of Caffeine Clobetasol Propionate Dutasteride Nicotinamide and Progesterone in TrichoFoam™, a Natural Vehicle for Hair Foams.

Background: Alopecia is a chronic dermatological disorder affecting men and women worldwide. Given the high incidence and significant impact on patients' well-being, options for managing and treating alopecia are essential. Topical available options remain limited and oral products may result in adverse effects. TrichoFoam™ is a ready-to-use foaming vehicle developed for compounding pharmacies and formulated with gentle, non-irritating, and sensory-pleasant ingredients.

Objective: The purpose of this study was to assess topical foams' physicochemical and microbiological stabilities of formulations compounded with TrichoFoam™ as the ready-touse vehicle.

Methods: HPLC analyses were conducted in a bracketed study covering concentrations of 0.1% to 2.0% of caffeine, 0.01% to 0.1% of clobetasol propionate, 0.1% to 0.25% of dutasteride, 0.25% to 0.50% of nicotinamide, and 0.25% to 2.5% of progesterone compounded with TrichoFoam™. Antimicrobial Effectiveness Testing was conducted at the beginning and end of the studies.

Results: Most formulations presented a beyond-use date of at least 90-180 days, except for clobetasol propionate, which showed compatibility for 14 days, and dutasteride 0.25%, which showed a BUD of 30 days.

Conclusion: This validates the stability of the active pharmaceutical ingredients from different pharmacological classes with TrichoFoam™, suggesting that this ready-to-use vehicle can be an excellent alternative for personalized alopecia treatment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.40
自引率
0.00%
发文量
62
期刊介绍: The International Journal of Pharmaceutical Compounding (IJPC) is a bi-monthly, scientific and professional journal emphasizing quality pharmaceutical compounding. IJPC is the only publication that covers pharmaceutical compounding topics relevant and necessary to empower pharmacists to meet the needs of today"s patients. No other publication features hands-on, how-to compounding techniques or the information that contemporary pharmacists need to provide individualized care.
期刊最新文献
Crushability Analysis of Immediate-Release Oral Tablets and Capsules from the 2020-22 FDA Novel Drug Approvals. Enhancing Hormonal Tablets Disintegration: The Role of Chitosan as an Alternative Disintegrant in Estradiol Tablet Formulation. Pharmaceutical Waters Used in Sterile and Nonsterile Compounding. Comparison of Oven Dried and Freeze Dried Orally Disintegrating Film (ODF) Formulations Containing Memantine Hydrochloride. Compatibility of Active Pharmaceutical Ingredients in Cleoderm™: A Comprehensive Study for Enhanced Topical Dermatological Treatments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1